J and J gears up for a clinical test of HIV vaccine efficacy

NICK PAUL TAYLOR | July 15, 2019

article image
Johnson and Johnson is gearing up to test a HIV vaccine in a 3,800 person clinical trial. The preparations follow animal studies that showed the vaccine offered better protection than earlier attempts to confer immunity to the virus. Efforts to develop HIV vaccines began in the early years of the HIV crisis, but few candidates made it to the clinic and those that did delivered underwhelming data. J&J bolstered its own efforts in the area through the $2.4 billion acquisition of Crucell in 2010. And, after 15 years of early-stage work, the Big Pharma is now poised to learn whether it can succeed where Merck, Sanofi and others failed. Talking to Bloomberg,  Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, said a trial of the vaccine candidate in 3,800 men who have sex with men will start later this year. Data could arrive in 2023.

Spotlight

Statistics & Data Corporation (SDC)

SDC is committed to providing experienced teams who will take ownership of your needs and are positively engaged in your projects. With biostatistics and data management services at our core, SDC offers full service clinical trial solutions that are tailored to fit your needs. Our scalable CRO services, via our diverse and complementary strategic partnerships, allow SDC to offer you the right team for your project.

OTHER ARTICLES
MEDICAL

Better Purification and Recovery in Bioprocessing

Article | August 2, 2021

In the downstream portion of any bioprocess, one must pick through the dross before one can seize the gold the biotherapeutic that the bioprocess was always meant to generate. Unfortunately, the dross is both voluminous and various. And the biotherapeutic gold, unlike real gold, is corruptible. That is, it can suffer structural damage and activity loss. When discarding the dross and collecting the gold, bioprocessors must be efficient and gentle. They must, to the extent possible, eliminate contaminants and organic debris while ensuring that biotherapeutics avoid aggregation-inducing stresses and retain their integrity during purification and recovery. Anything less compromises purity and reduces yield. To purify and recover biotherapeutics efficiently and gently, bioprocessors must avail themselves of the most appropriate tools and techniques. Here, we talk with several experts about which tools and techniques can help bioprocessors overcome persistent challenges. Some of these experts also touch on new approaches that can help bioprocessors address emerging challenges.

Read More
DIAGNOSTICS

Making Predictions by Digitizing Bioprocessing

Article | April 20, 2021

With advances in data analytics and machine learning, the move from descriptive and diagnostic analytics to predictive and prescriptive analytics and controls—allowing us to better forecast and understand what will happen and thus optimize process outcomes—is not only feasible but inevitable, according to Bonnie Shum, principal engineer, pharma technical innovation, technology & manufacturing sciences and technology at Genentech. “Well-trained artificial intelligence systems can help drive better decision making and how data is analyzed from drug discovery to process development and to manufacturing processes,” she says. Those advances, though, only really matter when they improve the lives of patients. That’s exactly what Shum expects. “The convergence of digital transformation and operational/processing changes will be critical for the facilities of the future and meeting the needs of our patients,” she continues. “Digital solutions may one day provide fully automated bioprocessing, eliminating manual intervention and enabling us to anticipate potential process deviations to prevent process failures, leading to real-time release and thus faster access for patients.” To turn Bioprocessing 4.0 into a production line for precision healthcare, real-time release and quickly manufacturing personalized medicines will be critical. Adding digitization and advanced analytics wherever possible will drive those improvements. In fact, many of these improvements, especially moving from descriptive to predictive bioprocessing, depend on more digitization.

Read More

Spotlight

Statistics & Data Corporation (SDC)

SDC is committed to providing experienced teams who will take ownership of your needs and are positively engaged in your projects. With biostatistics and data management services at our core, SDC offers full service clinical trial solutions that are tailored to fit your needs. Our scalable CRO services, via our diverse and complementary strategic partnerships, allow SDC to offer you the right team for your project.

Events